Literature DB >> 23820160

Percutaneous transplantation of human umbilical cord-derived mesenchymal stem cells in a dog suspected to have fibrocartilaginous embolic myelopathy.

Wook-Hun Chung1, Seon-Ah Park, Jae-Hoon Lee, Dai-Jung Chung, Wo-Jong Yang, Eun-Hee Kang, Chi-Bong Choi, Hwa-Seok Chang, Dae-Hyun Kim, Soo-Han Hwang, Hoon Han, Hwi-Yool Kim.   

Abstract

The use of human umbilical cord blood-derived mesenchymal stem cells for cell transplantation therapy holds great promise for repairing spinal cord injury. Here we report the first clinical trial transplantation of human umbilical cord (hUCB)-derived mesenchymal stem cells (MSCs) into the spinal cord of a dog suspected to have fibrocartilaginous embolic myelopathy (FCEM) and that experienced a loss of deep pain sensation. Locomotor functions improved following transplantation in a dog. Based on our findings, we suggest that transplantation of hUCB-derived MSCs will have beneficial therapeutic effects on FCEM patients lacking deep pain sensation.

Entities:  

Keywords:  dog; fibrocartilaginous embolic myelopathy; human umbilical cord-derived mesenchymal stem cells; percutaneous transplantation; xenotransplantaion

Mesh：

Year:  2013        PMID： 23820160      PMCID： PMC3885746          DOI： 10.4142/jvs.2013.14.4.495

Source DB:  PubMed          Journal:  J Vet Sci        ISSN： 1229-845X            Impact factor:   1.672


  12 in total

1.  Spinal cord compression studies. III. Time limits for recovery after gradual compression in dogs.

Authors:  I M TARLOV
Journal:  AMA Arch Neurol Psychiatry       Date:  1954-05

2.  Fibrocartilaginous embolism of the spinal cord diagnosed by characteristic clinical findings and magnetic resonance imaging in 26 dogs.

Authors:  Yuya Nakamoto; Tsuyoshi Ozawa; Kengo Katakabe; Koichi Nishiya; Nobuhiro Yasuda; Tadahisa Mashita; Yutaka Morita; Munekazu Nakaichi
Journal:  J Vet Med Sci       Date:  2009-02       Impact factor: 1.267

3.  Fibrocartilaginous embolism in 75 dogs: clinical findings and factors influencing the recovery rate.

Authors:  G Gandini; S Cizinauskas; J Lang; R Fatzer; A Jaggy
Journal:  J Small Anim Pract       Date:  2003-02       Impact factor: 1.522

4.  Axonal remyelination by cord blood stem cells after spinal cord injury.

Authors:  Venkata Ramesh Dasari; Daniel G Spomar; Christopher S Gondi; Christopher A Sloffer; Kay L Saving; Meena Gujrati; Jasti S Rao; Dzung H Dinh
Journal:  J Neurotrauma       Date:  2007-02       Impact factor: 5.269

5.  Magnetic resonance imaging findings in spinal cord infarction in three small breed dogs.

Authors:  Fredrik I Grünenfelder; Dominik Weishaupt; Ron Green; Frank Steffen
Journal:  Vet Radiol Ultrasound       Date:  2005 Mar-Apr       Impact factor: 1.363

6.  Human umbilical cord blood cells express neurotrophic factors.

Authors:  Cun-Gang Fan; Qing-Jun Zhang; Feng-Wu Tang; Zhi-Bo Han; Ge-Sheng Wang; Zhong-Chao Han
Journal:  Neurosci Lett       Date:  2005-02-12       Impact factor: 3.046

7.  Fibrocartilaginous embolic myelopathy in miniature schnauzers.

Authors:  J C Hawthorne; L J Wallace; W R Fenner; D J Waters
Journal:  J Am Anim Hosp Assoc       Date:  2001 Jul-Aug       Impact factor: 1.023

8.  Magnetic resonance imaging appearance of suspected ischemic myelopathy in dogs.

Authors:  Carley J Abramson; Laurent Garosi; Simon R Platt; Ruth Dennis; J Fraser McConnell
Journal:  Vet Radiol Ultrasound       Date:  2005 May-Jun       Impact factor: 1.363

9.  Fibrocartilaginous embolism of the spinal cord in dogs: review of 36 histologically confirmed cases and retrospective study of 26 suspected cases.

Authors:  L Cauzinille; J N Kornegay
Journal:  J Vet Intern Med       Date:  1996 Jul-Aug       Impact factor: 3.333

10.  Usefulness of an early diagnosis for the favorable prognosis of fibrocartilaginous embolism diagnosed by magnetic resonance imaging in 10 small- to middle-sized dogs.

Authors:  Yuya Nakamoto; Tsuyoshi Ozawa; Kengo Katakabe; Koichi Nishiya; Tadahisa Mashita; Yutaka Morita; Nobuhiro Yasuda; Yuki Ishii; Munekazu Nakaichi; Kazuhito Itamoto
Journal:  Vet Res Commun       Date:  2008-05-20       Impact factor: 2.459
View more
  6 in total

1.  Magnetic Resonance Imaging-Guided Transplantation of Neural Stem Cells into the Porcine Spinal Cord.

Authors:  Jason J Lamanna; Lindsey N Urquia; Carl V Hurtig; Juanmarco Gutierrez; Cody Anderson; Pete Piferi; Thais Federici; John N Oshinski; Nicholas M Boulis
Journal:  Stereotact Funct Neurosurg       Date:  2017-01-28       Impact factor: 1.875

Review 2.  Targeting Translational Successes through CANSORT-SCI: Using Pet Dogs To Identify Effective Treatments for Spinal Cord Injury.

Authors:  Sarah A Moore; Nicolas Granger; Natasha J Olby; Ingo Spitzbarth; Nick D Jeffery; Andrea Tipold; Yvette S Nout-Lomas; Ronaldo C da Costa; Veronika M Stein; Linda J Noble-Haeusslein; Andrew R Blight; Robert G Grossman; D Michele Basso; Jonathan M Levine
Journal:  J Neurotrauma       Date:  2017-03-22       Impact factor: 5.269

3.  Good manufacturing practice-compliant isolation and culture of human umbilical cord blood-derived mesenchymal stem cells.

Authors:  Phuc Van Pham; Ngoc Bich Vu; Vuong Minh Pham; Nhung Hai Truong; Truc Le-Buu Pham; Loan Thi-Tung Dang; Tam Thanh Nguyen; Anh Nguyen-Tu Bui; Ngoc Kim Phan
Journal:  J Transl Med       Date:  2014-02-24       Impact factor: 5.531

4.  The use of autologous neurogenically-induced bone marrow-derived mesenchymal stem cells for the treatment of paraplegic dogs without nociception due to spinal trauma.

Authors:  Omer Besalti; Zeynep Aktas; Pinar Can; Eylul Akpinar; Ayse Eser Elcin; Yasar Murat Elcin
Journal:  J Vet Med Sci       Date:  2016-06-10       Impact factor: 1.267

Review 5.  Challenges of stem cell therapies in companion animal practice.

Authors:  Min Hee Kang; Hee Myung Park
Journal:  J Vet Sci       Date:  2020-05       Impact factor: 1.672

Review 6.  Stem cells in canine spinal cord injury--promise for regenerative therapy in a large animal model of human disease.

Authors:  Barbara G McMahill; Dori L Borjesson; Maya Sieber-Blum; Jan A Nolta; Beverly K Sturges
Journal:  Stem Cell Rev Rep       Date:  2015-02       Impact factor: 5.739
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.